<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00242944</url>
  </required_header>
  <id_info>
    <org_study_id>H17-49</org_study_id>
    <nct_id>NCT00242944</nct_id>
  </id_info>
  <brief_title>Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS)</brief_title>
  <official_title>Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyoto University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yamaguchi University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juntendo University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyoto University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effects of pitavastatin and atorvastatin on
      coronary plaque volume in patients with acute coronary syndrome and to clarify the
      relationship between coronary plaque volume, serum lipids, and inflammation markers in order
      to determine the significance of intensive lipid lowering therapy in patients with acute
      coronary syndrome in Japan.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous mega trials have demonstrated that lipid lowering therapy with HMG-CoA reductase
      inhibitors (statins) reduces the incidence of major cardiovascular events by one-third, thus,
      the benefit of lipid lowering therapy has been substantiated. Such a benefit is significant
      especially for patients with coronary heart disease (CHD). The third report of the National
      Cholesterol Education Program Adult Treatment Panel (NCEP ATP-III) has suggested the
      advantage of more intensive lipid lowering therapy with a goal of reducing LDL-C below 70
      mg/dL for such patients categorized as very high risk. In Japan, Japan Atherosclerosis
      Society (JAS) Guidelines for Diagnosis and Treatment of Atherosclerotic Cardiovascular
      Diseases 2002 have recommended that an LDL-C goal for patients with coronary heart disease
      should be below 100 mg/dL. However, there is no satisfactory evidence yet for the need to
      lower LDL-C level less than the goal prescribed in Japan.

      Recently, research on diagnosis of coronary plaque has shown significant advances. The
      REVERSAL study in patients with a history of CHD, by diagnosis with intravascular ultrasound,
      suggested that intensive lipid lowering therapy with atorvastatin (80 mg/day) was associated
      with no growth of plaque (-0.4% compared to baseline), versus therapy with pravastatin (40
      mg/day) which showed a slight increase (2.7%) in plaque volume over 18 months. In Japan, the
      ESTABLISH study, a single center study, indicated that early intensive lipid lowering therapy
      with atorvastatin (20 mg/day) could induce a significant reduction in plaque volume in
      patients with acute coronary syndrome. However, this benefit has not been verified in
      multicenter trials in Japan. Further, no comparative investigation into the effect of various
      concomitant drugs on coronary plaque has been done.

      Pitavastatin is a chemically synthesized statin in Japan which has been marketed since late
      2003. Pitavastatin has an LDL-C lowering effect as strong as atorvastatin and also has a
      superior HDL-C elevating effect; meanwhile, the effect of pitavastatin on coronary plaque has
      not been reported.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>plaque volume</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>total cholesterol (TC)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>low-density lipoprotein (LDL)-cholesterol (LDL-C)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>high-density lipoprotein (HDL)-cholesterol (HDL-C)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL2-C</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL3-C</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>remnant like particles-cholesterol (RLP-C)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>small dense LDL-C</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-HDL-C</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-C/HDL-C</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apolipoprotein AI (apoA-I)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apoB</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apoE</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apoB/apoA-I</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>malondialdehyde-modified LDL (MDA-LDL)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phospholipids</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipoprotein(a) [Lp(a)]</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>high-sensitivity C-reactive protein (hs-CRP)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pentraxin 3</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>leukocytes</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>coronary plaque area at culprit region</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>minimal lumen diameter (MLD) and percent (%) stenosis</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major adverse cardiac events (cardiac death, Q or non-Q myocardial infarction and target vessel revascularization)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of deaths from any cause</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of adverse drug reactions</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">307</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pitavastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin</intervention_name>
    <description>Pitavastatin 4mg per day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin 20mg per day</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with written consent by their own volition after being provided sufficient
             explanation for their participation in this clinical trial

          -  Patients 20 years or older at the time of their consent

          -  Patients with hypercholesterolemia as defined by any of the following criteria:

               -  TC &gt;= 220 mg/dL;

               -  LDL-C &gt;= 140 mg/dL;

               -  Cholesterol-lowering treatment is necessary in accordance with the investigator's
                  judgement when LDL-C &gt;= 100 mg/dL or TC &gt;= 180 mg/dL.

          -  Patients who have been diagnosed with acute coronary syndrome

          -  Patients with successful percutaneous coronary intervention (PCI) by intravascular
             ultrasound (IVUS) guidance

          -  Patients having coronary plaques (&gt;= 500 Âµm in thickness or 20% or more in % plaque)
             at &gt;= 5 mm from the previously treated area in the same branch of coronary artery

        Exclusion Criteria:

          -  Patients with bypass graft or in-stent restenosis at the site of PCI

          -  Patients who had received PCI on the lesion in the past where the evaluation of
             coronary plaque volume is planned

          -  Patients who had plaques in a non-culprit site and might receive PCI during the
             treatment period

          -  Patients receiving lipid-lowering drugs (statins, fibrates, probucol, nicotinic acid
             or cholesterol absorption inhibitors)

          -  Patients with familial hypercholesterolemia

          -  Patients with cardiogenic shock

          -  Patients receiving cyclosporine

          -  Patients with any allergy to pitavastatin or atorvastatin

          -  Patients with hepatobiliary disorders

          -  Pregnant women, women suspected of being pregnant, or lactating women

          -  Patients with renal disorders or undergoing dialysis

          -  Patients who are ineligible in the opinion of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masunori Matsuzaki, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Professor of Medicine, Department of Cardiovascular Medicine, Yamaguchi University Graduate School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hiroyuki Daida, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Medicine, Department of Cardiovascular Medicine, Juntendo University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Takeshi Kimura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor of Medicine, Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Juntendo University School of Medicine</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8421</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamaguchi University Graduate School of Medicine</name>
      <address>
        <city>Ube</city>
        <state>Yamaguchi</state>
        <zip>755-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto University Graduate School of Medicine</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Miyauchi K, Kimura T, Morimoto T, Nakagawa Y, Yamagishi M, Ozaki Y, Hiro T, Daida H, Matsuzaki M. Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): rationale and design. Circ J. 2006 Dec;70(12):1624-8. Erratum in: Circ J. 2007 Jan;71(1):172.</citation>
    <PMID>17127811</PMID>
  </reference>
  <results_reference>
    <citation>Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M; JAPAN-ACS Investigators. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol. 2009 Jul 21;54(4):293-302. doi: 10.1016/j.jacc.2009.04.033.</citation>
    <PMID>19608026</PMID>
  </results_reference>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2005</study_first_submitted>
  <study_first_submitted_qc>October 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2005</study_first_posted>
  <last_update_submitted>December 16, 2009</last_update_submitted>
  <last_update_submitted_qc>December 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Masunori Matsuzaki</name_title>
    <organization>Yamaguchi University Graduate School of Medicine</organization>
  </responsible_party>
  <keyword>Acute coronary syndrome</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>Primary coronary intervention</keyword>
  <keyword>Hydroxymethylglutaryl-CoA reductase inhibitors</keyword>
  <keyword>coronary plaque</keyword>
  <keyword>Angioplasty, Transluminal, Percutaneous Coronary</keyword>
  <keyword>Ultrasonography, Interventional</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

